Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

He, Yanjuan; Jiang, Duanfeng; Zhang, Kaixuan; Zhu, Yinghong; Zhang, Jingyu; Wu, Xuan; Xia, Jiliang; Zhu, Yan; Zou, Lang; Hu, Jian; Cui, Yajuan; Zhou, Wen; Chen, Fangping

doi:10.7150/jca.61602

Cited by 8 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chidamide also exerted a synergistic effect with traditional antimyeloma agents, such as bortezomib. The combination of chidamide with bortezomib induced G0/G1 arrest and cell apoptosis, with increased ROS‐dependent DNA damage and impaired the cell cycle 47 . Additionally, chidamide was observed to cooperatively enhance the antimyeloma activity of bortezomib by repressing the autophagic degradation of ubiquitinated proteins 48 .…”

Section: Chidamide In Multiple Myelomamentioning

confidence: 99%

“…The combination of chidamide with bortezomib induced G0/G1 arrest and cell apoptosis, with increased ROS-dependent DNA damage and impaired the cell cycle. 47 Additionally, chidamide was observed to cooperatively enhance the antimyeloma activity of bortezomib by repressing the autophagic degradation of ubiquitinated proteins. 48 Moreover, the bortezomib-resistant myeloma cell line ANBL6-BR showed higher HDAC1 expression, and this cell line was more sensitive to chidamide than the wild-type cell line.…”

Section: The Treatment Of Multiple Myeloma With Chidamide In Preclini...mentioning

confidence: 99%

“…48 Moreover, the bortezomib-resistant myeloma cell line ANBL6-BR showed higher HDAC1 expression, and this cell line was more sensitive to chidamide than the wild-type cell line. 47 In clinical practice, an R/R MM patient was successfully treated with chidamide, bortezomib and dexamethasone. 49…”

Section: The Treatment Of Multiple Myeloma With Chidamide In Preclini...mentioning

confidence: 99%

“…Additionally, chidamide was observed to cooperatively enhance the antimyeloma activity of bortezomib by repressing the autophagic degradation of ubiquitinated proteins 48 . Moreover, the bortezomib‐resistant myeloma cell line ANBL6‐BR showed higher HDAC1 expression, and this cell line was more sensitive to chidamide than the wild‐type cell line 47 . In clinical practice, an R/R MM patient was successfully treated with chidamide, bortezomib and dexamethasone 49…”

Section: Chidamide In Multiple Myelomamentioning

confidence: 99%

See 3 more Smart Citations

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Cao

Xue

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

Epigenetic alterations frequently participate in the onset of hematological malignancies. Histone deacetylases (HDACs) are essential for regulating gene transcription and various signaling pathways. Targeting HDACs has become a novel treatment option for hematological malignancies. Chidamide is the first oral selective HDAC inhibitor for HDAC1, HDAC2, HDAC3, and HDAC10 and was first approved for the treatment of R/R peripheral T‐cell lymphoma by the China Food and Drug Administration in 2014. Chidamide was also approved under the name Hiyasta (HBI‐8000) in Japan in 2021. In vitro studies revealed that chidamide could inhibit proliferation and induce apoptosis via cell cycle arrest and the regulation of apoptotic proteins. In clinical studies, chidamide was also efficacious in multiple myeloma, acute leukemia and myelodysplastic syndrome. This review includes reported experimental and clinical data on chidamide monotherapy or chidamide treatment in combination with chemotherapy for various hematological malignancies, offering a rationale for the renewed exploration of this drug.

show abstract

Section: Chidamide In Multiple Myelomamentioning

confidence: 99%

Section: The Treatment Of Multiple Myeloma With Chidamide In Preclini...mentioning

confidence: 99%

Section: The Treatment Of Multiple Myeloma With Chidamide In Preclini...mentioning

confidence: 99%

Section: Chidamide In Multiple Myelomamentioning

confidence: 99%

See 2 more Smart Citations

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Cao

Xue

et al. 2022

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Like other targeted therapies, drug resistance also occurs commonly in MM patients. He et al reported that tucidinostat could reverse bortezomib resistance through enhanced ROS production and DNA damage (He et al, 2021). ABT199 (Venetoclax) is a selective BCL-2 inhibitor approved as a component of combination therapy for AML.…”

Section: Hematological Malignanciesmentioning

confidence: 99%

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Sun

Hong

Ning³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Histone deacetylase (HDAC) is one of the most characterized epigenetic modifiers, modulating chromatin structure and gene expression, which plays an important role in cell cycle, differentiation and apoptosis. Dysregulation of HDAC promotes cancer progression, thus inhibitors targeting HDACs have evidently shown therapeutic efficacy in multiple cancers. Tucidinostat (formerly known as chidamide), a novel subtype-selective HDAC inhibitor, inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Tucidinostat is approved in relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL), advanced breast cancer and R/R adult T-cell leukemia-lymphoma (ATLL). Compared with other HDAC inhibitors, tucidinostat shows notable antitumor activity, remarkable synergistic effect with immunotherapy, and manageable toxicity. Here, we comprehensively summarize recent advances in tucidinostat as both monotherapy and a regimen of combination therapy in both hematological and solid malignancies in clinic. Further studies will endeavor to identify more combination strategies with tucidinostat and to identify specific clinical biomarkers to predict the therapeutic effect.

show abstract

Histone deacetylase‐based dual targeted inhibition in multiple myeloma

Ferro

Pantazaka

Athanassopoulos

et al. 2023

Medicinal Research Reviews

View full text Add to dashboard Cite

Despite enormous advances in terms of therapeutic strategies, multiple myeloma (MM) still remains an incurable disease with MM patients often becoming resistant to standard treatments. To date, multiple combined and targeted therapies have proven to be more beneficial compared to monotherapy approaches, leading to a decrease in drug resistance and an improvement in median overall survival in patients. Moreover, recent breakthroughs highlighted the relevant role of histone deacetylases (HDACs) in cancer treatment, including MM. Thus, the simultaneous use of HDAC inhibitors with other conventional regimens, such as proteasome inhibitors, is of interest in the field. In this review, we provide a general overview of HDAC‐based combination treatments in MM, through a critical presentation of publications from the past few decades related to in vitro and in vivo studies, as well as clinical trials. Furthermore, we discuss the recent introduction of dual‐inhibitor entities that could have the same beneficial effects as drug combinations with the advantage of having two or more pharmacophores in one molecular structure. These findings could represent a starting‐point for both reducing therapeutic doses and lowering the risk of developing drug resistance.

show abstract

Chidamide, a subtype-selective histone deacetylase inhibitor, enhances Bortezomib effects in multiple myeloma therapy

Cited by 8 publications

References 40 publications

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Chidamide: Targeting epigenetic regulation in the treatment of hematological malignancy

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Histone deacetylase‐based dual targeted inhibition in multiple myeloma

Contact Info

Product

Resources

About